Definitive Contract W81XWH17C0069
Award Date
5/1/17
Potential Completion Date
12/31/19
Potential Value
$627K
Funding Federal Agency
Air Mobility Command
Contracting Federal Agency
Medical Command
Awardee
Ophirex, Inc.
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Fixed Price Level of Effort
Place of Performance
Corte Madera, CA 94925, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Small Business Innovation Research (SBIR) Phase II medical research and development contract awarded by the Defense Health Agency (DHA) to Ophirex, Inc., a small business located in Corte Madera, California. The contract, valued at $1,525,194.76, is for the development of a "Broad Spectrum Envenomation Treatment" to address snakebite injuries. The contract has a firm fixed price and a total small business set aside designation. This contract builds upon previous SBIR Phase...
This is a $9,407,618.00 firm fixed price definitive contract awarded by the Defense Health Agency to Ophirex, Inc., a small business, for the development of a broad-spectrum snakebite antidote. The contract is part of the U.S. Army Medical Research and Development Command's Small Business Innovation Research (SBIR) Phase III program, which provides for the continued research and development of technologies that have successfully completed Phases I and II. The contract aims to advance the...
This is a firm fixed price, definitive contract awarded by the Department of the Army Medical Command to Ophirex, Inc., a small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract, valued at $148,509.12, is for the development of a broad-spectrum envenomation treatment. Ophirex, a for-profit organization, has previously received SBIR Phase II and III awards from the Department of the Army Medical Command and the Defense Health Agency for related research...
Ophirex, Inc. has been awarded a firm fixed price definitive contract valued at $1,299,779 by the Department of the Army Medical Command. This contract is a Small Business Innovation Research Program Phase II award to further develop Ophirex's intravenous snakebite antidote varespladib. Specifically, the contract aims to improve recovery time following snakebite through metalloprotease inhibition. As a total small business set aside, this award will support Ophirex's continued medical research...
The Department of the Army Medical Command awarded Ophirex, Inc. a $10.6 million definitive contract to support research and development efforts for a COVID-19 treatment under the Small Business Innovation Research Program Phase III. The prime contractor will conduct work at its place of performance in Corte Madera, California from June 2020 through September 2023 under the firm fixed price contract, which has a total small business set aside designation. Specifically, Ophirex will perform...
This is a $3,849.30 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services. The contract is for the product "COBRA VENOM" and was awarded to Sigma-Aldrich, Inc., a foreign-owned, for-profit organization that provides laboratory supplies, chemicals, and materials to support scientific research and development across multiple federal agencies. The award is not...
This is a firm-fixed price purchase order awarded by the Department of State (DOS) Bureau of Administration to CRO LLC, a Service-Disabled Veteran-Owned Small Business (SDVOSB). The contract, valued at $75,600.00, is for the delivery of polyserp snake antivenoms. CRO LLC specializes in manufacturing medical equipment for prehospital, austere, and operational medicine, and has received previous prime contract awards from the Department of the Army Medical Command, the DOS Bureau of...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This federal contract award, valued at $330,136,246.14, was granted by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to 4J Therapeutics Inc., a self-certified small disadvantaged business. The contract's objective is to demonstrate the versatility and efficacy of 4J Therapeutics' programmable antiviral technology platform by assembling a preclinical package for LNA14, performing a Phase 1a...
This is a $1,099,999.92 Firm Fixed Price SBIR Phase II contract awarded by the Joint PEO Chemical and Biological Defense, a component of the U.S. Army, to Consegna Pharma Inc., a small disadvantaged business. The contract is for the development of a long-duration opioid overdose antagonist. This award follows a prior $167,421 SBIR Phase I contract Consegna received from the Army for additional pharmaceutical research and development. Consegna has also received several grants from the National...